Targeted Oncologics Will Sustain High Prices With Clear Benefits, GSK Says

The high price tags of targeted therapies will continue to be supported as specific populations are identified where the oncologics can show a clear benefit, according to GlaxoSmithKline Chairman of R&D Tachi Yamada